Imfinzi + Imjudo, EU approved for patients with advanced lung cancer and non-small cell lung cancer: AstraZeneca

Published Date: 01 Mar 2023

United Kingdom: AstraZeneca has announced that it has received European Union (EU) approval for the immuno-oncology drug combination Imfinzi (active ingredient durvalumab) and Imjudo (tremelimumab).

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

When it comes to obesity-related cancers, where you shop for food matters

2.

Screening for prostate cancer: is it time to give up digital rectal examination?

3.

Underprescribed for Alcohol Use Disorder is pharmacotherapy.

4.

Recent research suggests that vitamin supplements may increase the risk of developing cancer.

5.

Life quality after childhood cancer is quantifiable thanks to outcome indicators.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot